

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 December 2005 (08.12.2005)


PCT

(10) International Publication Number
WO 2005/115514 A1

- (51) International Patent Classification⁷: **A61M 5/24**
- (21) International Application Number:
PCT/GB2005/002135
- (22) International Filing Date: 27 May 2005 (27.05.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- | | | |
|-----------|---------------------------|----|
| 0412050.7 | 28 May 2004 (28.05.2004) | GB |
| 0412055.6 | 28 May 2004 (28.05.2004) | GB |
| 0412053.1 | 28 May 2004 (28.05.2004) | GB |
| 0412049.9 | 28 May 2004 (28.05.2004) | GB |
| 0412061.4 | 28 May 2004 (28.05.2004) | GB |
| 0412054.9 | 28 May 2004 (28.05.2004) | GB |
| 0412057.2 | 28 May 2004 (28.05.2004) | GB |
| 0412056.4 | 28 May 2004 (28.05.2004) | GB |
| 0412048.1 | 28 May 2004 (28.05.2004) | GB |
| 0412051.5 | 28 May 2004 (28.05.2004) | GB |
| 0507010.7 | 6 April 2005 (06.04.2005) | GB |
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **HARRISON, Nigel, David** [GB/GB]; PA Consulting Group, Cambridge Technology Centre, Melbourn, Hertfordshire SG8 6DP (GB). **HABESHAW, Rosemary, Louise** [GB/GB]; PA Consulting Group, Cambridge Technology Centre, Melbourn, Hertfordshire SG8 6DP (GB).
- (74) Agents: **TUNSTALL, Christopher, Stephen** et al.; Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
- (71) Applicant (for all designated States except US): **CILAG AG INTERNATIONAL** [CH/CH]; Landis & Gyrstrasse 1, CH-6300 Zug (CH).

[Continued on next page]

(54) Title: INJECTION DEVICE



(57) Abstract: A syringe (114) is received with a housing, the syringe having a bore terminating at a forward end in a hypodermic needle (118) and at a rearward end in a flared opening (210) in which a bung (134a) having a bore (206) surrounded by a skirt (208) is inserted. A drive element (134) has a forward end consisting of a substantially flat annular region (200) that bears upon the skirt of the bung and surrounds a conical middle region (202) that is received in the bore (206) of the bung. An actuator advances the drive element (134) so as to advance the bung and discharge the contents of the syringe through the needle (118). The opening (210) in the rear of the glass syringe is flared by being provided with a radius. The combination of the radius at the opening and the projecting conical middle region of the drive element allows misalignments of the two to be managed during automated assembly.



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

Injection DeviceBackground Technology

The present invention is concerned with injection devices of the type that include a
5 housing, a syringe received within the housing, the syringe having a bore in which a
discharge piston having a bore is inserted, a drive element and an actuator for advancing
the drive element so as to advance the discharge piston and discharge the contents of the
syringe through its discharge nozzle.

10 These days, nearly everything is manufactured by machines. In some circumstances,
machines are more reliable than manual labour and are they are very much less expensive.
However, there is one faculty of a production line worker that, hitherto, machines have
been unable to reproduce, and are unlikely to be able to do so for a long time to come. If a
production line worker drops a part of the thing being manufactured, he may pick it up or
15 he may select another from the parts bin. If a part is damaged, he may discard it. If the
assembly operation he is undertaking is complex, he will ensure that the parts are properly
aligned and assembled. He does all of these things because he is able to adapt to different
circumstances and to use his judgment. Machines cannot.

20 During automated assembling of injection devices of the type mentioned above, there are a
number of critical steps that need to be performed accurately and properly. Difficulties in
performing these steps may arise from tight component tolerances or from the use of
fragile components, such as glass hypodermic syringes. The particular assembly step with
which the present invention is concerned is that of getting the drive element into the bore
25 of the syringe, to which a number of challenges attach. Firstly, to act on the outer diameter
of the syringe piston, it is necessary for the drive element to have a flat end face that is a
close fit in the syringe bore. Secondly, this flat end face presents the risk that the drive
element may jam onto the end of the syringe, particularly if there is any misalignment
between the components. Thirdly, if automation is used to assemble the devices a jam
30 between the drive element and the syringe could result in damage to the device or even
breakage of the syringe. Finally, even if this operation is done by hand, it is often
necessary to do it blind.

Summary of the Invention

It is an object of the present invention to provide a construction of injection device in which possible misalignment between the drive element and the syringe bore during assembly is already accounted for and does not so easily lead to a jam between the drive
5 element and the syringe.

Accordingly, an injection device according to the present invention comprises:

a housing;

a syringe received within the housing, the syringe having a bore terminating at a
10 forward end in a discharge nozzle and at a rearward end in a flared opening in which a discharge piston having a bore is inserted;

a drive element having a forward end consisting of a substantially flat edge region that is adapted to bear upon the discharge piston of the syringe and surrounds a projecting middle region that is adapted to be received in the bore of the discharge piston; and

15 an actuator for advancing the drive element so as to advance the discharge piston and discharge the contents of the syringe through the discharge nozzle.

The combination of the flared opening to the syringe bore and the projecting middle region of the drive element allows the problems associated with mild misalignments of the two to
20 be overcome. This is because the projecting middle region either passes straight into the end of the syringe, or it contacts the flared opening which guides it towards the centre of the syringe. Coupled with force sensors on the assembly machines, this arrangement will allow the appropriate automatic adjustment to be made to the alignment of the two parts.

25 Alternatively, and this is thought to be better because it does not rely on force sensors or other sophisticated modifications of the assembly machines, any misalignment is automatically corrected in full. This can be achieved if the flared opening in the syringe and the substantially flat edge and projecting middle regions of the forward end of the drive element are so shaped and dimensioned that axial misalignment between the syringe
30 and the drive element during assembly of the injection device are corrected by, firstly, the projecting middle region of the forward end of the drive element riding up the flared opening of the syringe to a point at which, secondly, the substantially flat edge region of

the forward end of the drive element makes contact with and rides up the flared opening of the syringe to align the drive element in the bore of the syringe.

The appropriate amount of flaring of the opening will depend upon a number of variables.

- 5 Take a line formed by the intersection of the flared opening of the syringe and a plane that passes through the axis of the syringe bore. Preferably, this line possesses a radius of curvature of between 33% and 100% of the radius of the syringe bore. In the preferred embodiment, it possesses a radius of curvature of between 1 mm and 3 mm. This radius of curvature may be an instantaneous radius of curvature; it may be an average radius of
- 10 curvature; it may be a minimum radius of curvature.

- In embodiments in which the shape and dimensions of the flared opening in the syringe and the substantially flat edge and projecting middle regions of the forward end of the drive element are designed to correct axial misalignment in full, this radius of curvature
- 15 should preferably be greater than the maximum radial extent of the substantially flat edge region of the forward end of the drive element. Better results are obtained if it is at least 50% greater than the maximum radial extent of the substantially flat edge region of the forward end of the drive element. Even better results follow if it is at least 70% greater.

- 20 To allow all directions of axial misalignment to be dealt with equally, the flared opening of the syringe is preferably substantially a surface of revolution about the axis of the syringe bore.

The present invention also extends to an injection device comprising:

- 25 a housing adapted to receive a syringe having a bore terminating at a forward end in a discharge nozzle and at a rearward end in a flared opening in which a discharge piston having a bore is inserted; and
- a drive element that is adapted to bear upon the discharge piston of the syringe; and
- an actuator for advancing the drive element so as to advance the discharge piston
- 30 and discharge the contents of the syringe through the discharge nozzle, the forward end of the drive element consisting of a substantially flat edge region surrounding a projecting middle region.

Normally, the forward end of the drive element has a cross-sectional area in the range 6.5 mm^2 to 110 mm^2 , preferably $27.3 \text{ mm}^2 \pm 8\%$.

Again, to allow all directions of axial misalignment to be dealt with equally, the forward
5 end of the drive element may be substantially circular in cross-section. In that case, the forward end of the drive element normally has a radius in the range 1.45 mm to 5.9 mm , preferably $2.95 \text{ mm} \pm 4\%$.

The substantially flat edge region of the forward end of the drive element may account for
10 between 25% and 50% of the total area of the forward end of the drive element, preferably $37 \pm 3\%$ of the total area of the forward end of the drive element.

Again, to allow all directions of axial misalignment to be dealt with equally, the substantially flat edge region of the forward end of the drive element may be substantially
15 annular. Preferably, the inner diameter of the substantially flat annular region is $61 \pm 2\%$ of the outer diameter.

Again, to allow all directions of axial misalignment to be dealt with equally, the projecting middle region of the forward end of the drive element is substantially circular in shape. For
20 reasons that will be obvious, the projecting middle region of the forward end of the drive element preferably tapers from the substantially flat edge region to a neb. It is thought that best results may be obtained if the projecting middle region of the forward end of the drive element tapers at an average angle of between $35 \pm 10^\circ$ to the longitudinal axis of the drive element. For example, the projecting middle region of the forward end of the drive element
25 may be substantially conical or frustoconical with an included cone angle of $65 \pm 5^\circ$.

Brief Description of the Drawings

The present invention will now be describe by way of example with reference to the accompanying drawings, in which:

30 figure 1 shows in perspective an injection device of the type to which the present invention is applicable;

figure 2 shows in section the injection device of figure 1 before actuation;

figure 3 shows an enlarged portion of figure 2; and

figure 4 is a perspective view of the drive element of figures 1-3.

Detailed Description of the Preferred Embodiments

Figure 1 shows an injection device 110 having a housing 112 with a proximal end 101 and
5 a distal end 102. All parts are injection-moulded. The housing 112 has a trigger 111 which projects through the housing 112 and which can be actuated by pressing down on its upper surface 111a. There is a indicator opening 113 in the housing located adjacent the proximal end 101.

10 Figure 2 shows the housing 112 containing a hypodermic syringe 114 of conventional type, including a syringe body 116 terminating at one end in a hypodermic needle 118 and at the other in a flange 120. The conventional plunger and bung that would normally be used to discharge the contents of the syringe 114 manually have been removed and replaced with a drive element 134 which includes a bung 134a. This drive element 134 constrains a drug
15 124 to be administered within the syringe body 116. Whilst the syringe illustrated is of hypodermic type, this need not necessarily be so. Transcutaneous or ballistic dermal and subcutaneous syringes may also be used with the injection device of the present invention. As illustrated, the housing includes a return drive which here takes the form of a compression return spring 126 that biases the syringe 114 from an extended position in
20 which the needle 118 extends from an aperture 128 in the housing 112 to a retracted position in which the discharge nozzle 118 is contained within the housing 112.

The housing 112 includes a support member which, as shown in figure 2, takes the form of a cylindrical insert 122. The cylindrical insert 122 has, on its inner surface, a support
25 surface 122a which connects with one end of the return spring 126. The other end of the return spring 126 acts on the syringe 114 via a syringe carrier 127. The support surface 122a is provided, as shown in figure 2, by a rim on the inner surface of the cylindrical insert 122. The support surface 122a is positioned beyond the indicator opening 113 away from the proximal end 101 of the housing 112. The return spring 126 connects with the
30 support surface 122a on its end which is located away from the proximal end 101 of the housing 112 and its other end acts on the syringe carrier 127 beyond the support surface 122a from the proximal end 101 of the housing 112. This way, the return spring 126, which surrounds the syringe 114 and syringe carrier 127, cannot be seen through the

indicator opening 113 at any time before, during or after triggering of the injection device 110. The cylindrical insert 122 forms a window in the indicator opening 113 formed from transparent material so that the contents of the syringe 114 can be viewed through the indicator opening 113.

5

At the other end of the housing 112 is a forward drive, which here takes the form of a compression drive spring 130. Drive from the drive spring 130 is transmitted via a multi-component drive to the syringe 114 to advance it from its retracted position to its extended position and discharge its contents through the needle 118. The drive accomplishes this task by acting directly on the drug 124 and the syringe 114. Static friction between the drive element 134 and the syringe body 116 initially ensures that they advance together, until the return spring 126 bottoms out or the syringe body 116 meets some other obstruction (not shown) that retards its motion.

15 The multi-component drive between the drive spring 130 and the syringe 114 consists of three principal components. A drive sleeve 131 takes drive from the drive spring 130 and transmits it to a first drive element 132. This in turn transmits drive via a damping fluid to a second drive element, the drive element 134 already mentioned.

20 The first drive element 132 includes a hollow stem 140, the inner cavity of which forms a collection chamber 142 in communication with a vent 144 that extends from the collection chamber through the end of the stem 140. The second drive element 134 includes a blind bore 146 that is open at one end to receive the stem 140 and closed at the other. As can be seen, the bore 146 and the stem 140 defining a fluid reservoir 148, within which the
25 damping fluid is contained.

The trigger 111, when operated, serves to decouple the drive sleeve 131 from the housing 112, allowing it to move relative to the housing 112 under the influence of the drive spring 130. The operation of the device is then as follows.

30

Initially, the drive spring 130 moves the drive sleeve 131, the drive sleeve 131 moves the first drive element 132 and the first drive element 132 moves the second drive element 134. The second drive element 134 moves and, by virtue of static friction and hydrostatic

forces acting through the drug 124 to be administered, moves the syringe body 116 against the action of the return spring 126. The return spring 126 compresses and the hypodermic needle 118 emerges from the exit aperture 128 (not shown) of the housing 112. This continues until the return spring 126 bottoms out or the syringe body 116 meets some other
5 obstruction (not shown) that retards its motion. Because the static friction between the second drive element 134 and the syringe body 116 and the hydrostatic forces acting through the drug 124 to be administered are not sufficient to resist the full drive force developed by the drive spring 130, at this point the second drive element 134 begins to move within the syringe body 116 and the drug 124 begins to be discharged. Dynamic
10 friction between the second drive element 134 and the syringe body 116 and hydrostatic and hydrodynamic forces now acting through the drug 124 to be administered are, however, sufficient to retain the return spring 126 in its compressed state, so the hypodermic needle 118 remains extended.

15 Before the second drive element 134 reaches the end of its travel within the syringe body 116, so before the contents of the syringe have fully discharged, protrusions (not shown) on the first drive element 132 reach a constriction 137 within the housing 112. The constriction 137 moves the protrusions inwards so that the first drive element 136 is no longer coupled to the second drive element 134. Once this happens, the first drive element
20 136 no longer acts on the second drive element 134, allowing the first drive element 132 to move relative to the second drive element 134.

Because the damping fluid is contained within a reservoir 148 defined between the end of the first drive element 132 and the blind bore 146 in the second drive element 134, the
25 volume of the reservoir 146 will tend to decrease as the first drive element 132 moves relative to the second drive element 134 when the former is acted upon by the drive spring 130. As the reservoir 148 collapses, damping fluid is forced through the vent 144 into the collection chamber 142. After release of the drive spring 130, some of the force exerted by the drive spring 130 does work on the damping fluid, causing it to flow through the
30 constriction formed by the vent 144; the remainder acts hydrostatically through the fluid and through friction between the first and second drive elements 132, 134, thence via the second drive element 134. Losses associated with the flow of the damping fluid do not attenuate the force acting on the body of the syringe to a great extent. Thus, the return

spring 126 remains compressed and the hypodermic needle remains extended.

After a time, the second drive element 134 completes its travel within the syringe body 116 and can go no further. At this point, the contents of the syringe 114 are completely
5 discharged and the force exerted by the drive spring 130 acts to retain the second drive element 134 in its terminal position and to continue to cause the damping fluid to flow through the vent 144, allowing the first drive element 132 to continue its movement.

Before the reservoir 148 of fluid is exhausted, flexible latch arms 133 linking the drive
10 sleeve 131 with the first drive element 132 are no longer forced to engage the drive sleeve 131 by protrusions 133a on the second drive element 134. Once this happens, the drive sleeve 131 acts no longer on the first drive element 132, allowing them to move relative to each other. At this point, of course, the syringe 114 is released, because the forces developed by the drive spring 130 are no longer being transmitted to the syringe 114, and
15 the only force acting on the syringe will be the return force from the return spring 126. Thus, the syringe 114 is now returned to its retracted position and the injection cycle is complete.

All this takes place, of course, only once the cap 115 has been removed from the end of the
20 housing 112. As can be seen from figure 2, the end of the syringe 114 is sealed with a boot 123.

As discussed above and illustrated in figures 3 and 4, the drive element 134 terminates at its forward end in a flat annular region 200 that surrounds a substantially conical middle
25 region 202 terminating in a neb 204. The rubber bung 134a possesses a central bore 206 in which the conical middle region 202 and the neb 204 are received and a skirt 208 that is borne upon by the annular flat region of the end of the drive element 134. The opening 210 in the rear of the glass syringe is flared, in this case by being provided with a radius at region 212. This radius is provided around the whole of the syringe bore opening and thus
30 forms a surface of revolution.

The combination of the radius at regions 212 of the opening 210 to the syringe bore and the projecting conical middle region 202 and the neb 204 of the drive element allows

misalignments of the two to be managed. This is because the conical middle region 202 and the neb 204 either pass straight into the opening 210 of the syringe, or contact the radius at regions 212, which guides them towards the centre of the syringe bore. The radius at regions 212 and the substantially flat annular region and the central conical portion 202 and neb 204 of the drive element 134 are so shaped and dimensioned that axial misalignment between the syringe 114 and the drive element 134 during assembly of the injection device are corrected by, firstly, the conical middle region 202 of the drive element riding up the radius at region 212 to a point at which, secondly, the substantially flat annular region 200 of the drive element 134 also makes contact with and rides up the radius at region 212, to align the drive element 134 in the bore of the syringe 114.

In this preferred embodiment of the invention, the inner diameter of the bore of the syringe 114 is 6.35 ± 0.1 mm. The appropriate radius to be provided at regions 212 depends a number of variables. A typical radius may be between 33% and 100% of the radius of the syringe bore; in this preferred embodiment, it possesses a radius of curvature of between 1 mm and 3 mm. Since in this embodiment, the shape and dimensions of the flared opening in the syringe and the substantially flat annular and conical middle regions of the drive element 134 are designed to correct axial misalignment in full, this radius of curvature should preferably be greater than the maximum radial extent of the substantially flat annular region of the drive element 134. Better results are obtained if it is at least 50% greater than the maximum radial extent of the substantially flat edge region of the forward end of the drive element. Even better results follow if it is at least 70% greater. In this embodiment, a radius of 2 mm is preferred, which compares with a maximum radial extent of the substantially flat annular region 200 of the drive element 134 of about 1.15 mm.

25

The drive element 134 itself has a diameter at its forward of 5.9 ± 0.22 mm (i.e. $\pm 4\%$) and thus its cross-sectional area is $27.3 \text{ mm}^2 \pm 8\%$. The diameter of the base of the conical middle portion 202 is $3.6 \text{ mm} \pm 4\%$, which accounts for about 63% of the total area of the end of the drive element 134; the remaining 37% is accounted for by the flat annular region 200. The conical middle region of the forward end of the drive element has an included cone angle of $65 \pm 5^\circ$, which means that the sides of the cone taper at about 32.5° from the longitudinal axis of the drive element 134. These various preferred dimensions and angles make up a device that has been found to work extremely well.

A drive element 134 shaped in the way described has further advantages. If it is desired to reduce the dose volume of the device, this is easily done by inserting, during the assembly operation, an additional drive element between element 134 and the bung 134a. At its
5 forward end, the additional drive element should reproduce exactly the shape and dimensions of the drive element 134; at its rearward end, it should reproduce the shape and dimensions of the bore and skirt of the bung 134a. Thus, to the drive element 134, the additional drive element will be indistinguishable from the bung 134a; to the bung 134a, it will be indistinguishable from the drive element 134.

Claims

1. An injection device comprising:
a housing;
5 a syringe received within the housing, the syringe having a bore terminating at a forward end in a discharge nozzle and at a rearward end in a flared opening in which a discharge piston having a bore is inserted;
a drive element having a forward end consisting of a substantially flat edge region that is adapted to bear upon the discharge piston of the syringe and surrounds a projecting
10 middle region that is adapted to be received in the bore of the discharge piston; and
an actuator for advancing the drive element so as to advance the discharge piston and discharge the contents of the syringe through the discharge nozzle.
2. An injection device according to claim 1 in which the flared opening in the syringe
15 and the substantially flat edge and projecting middle regions of the forward end of the drive element are so shaped and dimensioned that axial misalignment between the syringe and the drive element during assembly of the injection device are corrected by, firstly, the projecting middle region of the forward end of the drive element riding up the flared opening of the syringe to a point at which, secondly, the substantially flat edge region of
20 the forward end of the drive element rides up the flared opening of the syringe to align the drive element in the bore of the syringe.
3. An injection device according to claim 2 in which the line formed by the intersection of the flared opening of the syringe and a plane that passes through the axis of
25 the syringe bore possesses a radius of curvature of between 33% and 100% of the radius of the syringe bore.
4. An injection device according to claim 2 in which the line formed by the intersection of the flared opening of the syringe and a plane that passes through the axis of
30 the syringe bore possesses a radius of curvature of between 1 mm and 3 mm.
5. An injection device according to claim 3 or claim 4 in which the said radius of curvature is an average radius of curvature.

6. An injection device according to claim 3 or claim 4 in which the said radius of curvature is a minimum radius of curvature.
- 5 7. An injection device according to any one of claims 3-6 in which the said radius of curvature is greater than the maximum radial extent of the substantially flat edge region of the forward end of the drive element.
8. An injection device according to claim 7 in which the said radius of curvature is at
10 least 50% greater than the maximum radial extent of the substantially flat edge region of the forward end of the drive element.
9. An injection device according to claim 7 in which the said radius of curvature is at
15 least 70% greater than the maximum radial extent of the substantially flat edge region of the forward end of the drive element.
10. An injection device according to any preceding claim in which the flared opening of the syringe is substantially a surface of revolution about the axis of the syringe bore.
- 20 11. An injection device comprising:
a housing adapted to receive a syringe having a bore terminating at a forward end in a discharge nozzle and at a rearward end in a flared opening in which a discharge piston having a bore is inserted; and
a drive element that is adapted to bear upon the discharge piston of the syringe; and
25 an actuator for advancing the drive element so as to advance the discharge piston and discharge the contents of the syringe through the discharge nozzle, the forward end of the drive element consisting of a substantially flat edge region surrounding a projecting middle region.
- 30 12. An injection device according to any preceding claim in which the forward end of the drive element has a cross-sectional area in the range 6.5 mm^2 to 110 mm^2 .
13. An injection device according to claim 12 in which the forward end of the drive

element has a cross-sectional area of $27.3 \text{ mm}^2 \pm 8\%$.

14. An injection device according to any preceding claim in which the forward end of the drive element is substantially circular in cross-section.

5

15. An injection device according to claim 14 in which the forward end of the drive element has a radius in the range 1.45 mm to 5.9 mm.

16. An injection device according to claim 15 in which the forward end of the drive
10 element has a radius of $2.95 \text{ mm} \pm 4\%$.

17. An injection device according to any preceding claim in which the substantially flat edge region of the forward end of the drive element accounts for between 25% and 50% of the total area of the forward end of the drive element.

15

18. An injection device according to claim 17 in which the substantially flat edge region of the forward end of the drive element accounts for $37 \pm 3\%$ of the total area of the forward end of the drive element.

20 19. An injection device according to any preceding claim in which the substantially flat edge region of the forward end of the drive element is substantially annular.

20. An injection device according to claim 19 in which the inner diameter of the substantially flat annular region is $61 \pm 2\%$ of the outer diameter.

25

21. An injection device according to any preceding claim in which the projecting middle region of the forward end of the drive element is substantially circular in shape.




22. An injection device according to any preceding claim in which the projecting
30 middle region of the forward end of the drive element tapers from the substantially flat edge region to a neb.


23. An injection device according to claim 22 in which the projecting middle region of

the forward end of the drive element tapers at an average angle of between $35 \pm 10^\circ$ to the longitudinal axis of the drive element.

24. An injection device according to claim 22 or claim 23 in which the projecting
5 middle region of the forward end of the drive element is substantially conical or frustoconical.

25. An injection device according to claim 24 in which the conical or frustoconical region of the forward end of the drive element has an included cone angle of $65 \pm 5^\circ$.








Fig. 3




Fig. 4

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2005/002135

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61M5/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/87384 A (NOVO NORDISK A/S) 22 November 2001 (2001-11-22) abstract; figures	1
Y	-----	2-25
Y	US 4 521 237 A (LOGOTHETIS ET AL) 4 June 1985 (1985-06-04) abstract; figures 5-7	2-25
X	US 5 779 668 A (GRABENKORT ET AL) 14 July 1998 (1998-07-14) column 7, line 15 - column 8, line 45; figure 8	1
Y	-----	2-25
Y	EP 0 516 473 A (OWEN MUMFORD LIMITED) 2 December 1992 (1992-12-02) cited in the application abstract; figures	2-25

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

5 September 2005

Date of mailing of the international search report

09/09/2005

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Ehrsam, F

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2005/002135

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0187384 A	22-11-2001	AU 5824301 A WO 0187384 A1 EP 1289579 A1 JP 2003533288 T US 2001053893 A1	26-11-2001 22-11-2001 12-03-2003 11-11-2003 20-12-2001
US 4521237 A	04-06-1985	NONE	
US 5779668 A	14-07-1998	AT 252400 T AU 712959 B2 AU 5373796 A CA 2216926 A1 DE 69630444 D1 DE 69630444 T2 DK 821599 T3 EP 0821599 A1 ES 2210355 T3 JP 11504536 T PT 821599 T WO 9630066 A1	15-11-2003 18-11-1999 16-10-1996 03-10-1996 27-11-2003 12-08-2004 01-03-2004 04-02-1998 01-07-2004 27-04-1999 31-03-2004 03-10-1996
EP 0516473 A	02-12-1992	DE 69208287 D1 DE 69208287 T2 EP 0516473 A1 JP 3292747 B2 JP 5161712 A US 5300030 A	28-03-1996 18-07-1996 02-12-1992 17-06-2002 29-06-1993 05-04-1994